(epinephrine) Injection


SYMJEPI® (epinephrine) Injection is indicated for the emergency treatment of allergic reactions (Type 1- including anaphylaxis) to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.

SYMJEPI 0.15mg is intended for immediate administration in patients who weigh 33 to 66 pounds; SYMJEPI 0.3mg is intended for immediate administration in patients who weigh 66 pounds or more and who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

SYMJEPI is available in pharmacies across the United States.

SYMJEPI Resources

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please visit for more information
Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.